AMRX Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Amneal Pharmaceuticals (NASDAQ: AMRX)
›
Amneal Pharmaceuticals (NASDAQ: AMRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 8,700 employees.
The shares were at 21.38 USD on 13 November 2026, up 79.7% over 52 weeks. Its 52-week range is 11.39 USD to 22.07 USD: the price is 3.1% below the high and 87.7% above the low.
At a market capitalisation of 7.45B USD, it trades at 53.4 times trailing earnings and 17.3 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 25.0, a premium of 113% for AMRX.
Amneal Pharmaceuticals reports return on equity of -101.8%, an operating margin of 16.7% and revenue up 10.0% year over year.
Its debt exceeds its cash by 3.12B USD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 24.29 USD is 13.6% above the current price. The next earnings report is expected on 26 February 2027.